COVID-19 Vaccine Sponsors’ Pledge To Wait For Phase III Helps US FDA
The move reduces the pressure on the companies to rush development, but also relieves burden on the FDA to approve a candidate too soon.
You may also be interested in...
US HHS turns to COVID-19 vaccine distributor to assemble vaccine administration kits, citing revised vaccine delivery schedule.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
Missteps on convalescent plasma and the revoked authorization of hydroxychloroquine – paired with US president Trump’s cheerleading for the rapid approval of a COVID-19 vaccine – has eroded public trust in the US FDA. Can a safety and efficacy pledge from vaccine developers tamp down public skepticism?